Supplemental Figure 1. Study Design.

For participants who terminated the study early, an Early Termination Visit was conducted at which clinical and safety assessments were performed.

For the first 4 monthly injections, participants returned to the study site every 14 (±2), then every 28 (±5) days for the remainder of the study.

DB, double-blind; EOS, End of Study; F/U, follow-up.

